Chronic lung infections represent a major cause of morbidity in patients with cystic fibrosis. Aurélie Tasiemski from the Centre for Infection and Immunity of Lille (CNRS UMR9017, INSERM U1019, Univ. Lille, IPL) He explores the oceans in search of a miracle cure. His idea: to search the abyss for novel molecules potentially capable of eliminating infectious agents. Naturally adapted to extreme environments and subjected to significant chemical fluctuations the spring worm hydrothermal deep Alvinella pompejana This offers several advantages. The researcher isolated an antimicrobial peptide called alvinellacin from this worm. This peptide exerts bactericidal and anti-biofilm activity on several bacterial strains, some of which are multi-resistant to antibiotics. Alvinellacin also protects against infection with Pseudomonas aeruginosa, a bacterium frequently found in patients with cystic fibrosisAlvinellacin therefore appears to be a promising candidate for the development of new stratégies therapeutic salary. chronic respiratory infections associated with cystic fibrosis.
Bioinspired Antimicrobial Strategy: An Extremophile Deep Sea Peptide to Combat Cystic Fibrosis Infections Caused by Pseudomonas aeruginosa and Staphylococcus aureus
Céline Boidin-Wichlacz, Marc Maresca, Teddy Grandjean, Axelle Grandé, Orane Huchez, Katy Jeannot, Rémi Desmet, Benoît Snella, Nicolas Vidal, Laure Genet, Stéphanie Caby, Magalie Sénéchal, Sophie Guillier, Fabienne Ripoll-Neulat, Oleg Melnyk, Muriel Pichavant, Aurélie Tasiemski
marine drugs. 2026 May 5; 24 (5): 164. doi: 10.3390/md24050164.
U1019 – UMR9017 “Lille Infection and Immunity Center” – University of Lille, CNRS, Inserm, Pasteur Institute of Lille, Lille University Hospital
